Generali Investments CEE investicni spolecnost a.s. Invests $2.45 Million in Pfizer Inc. (NYSE:PFE)

Generali Investments CEE investicni spolecnost a.s. acquired a new position in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 92,150 shares of the biopharmaceutical company’s stock, valued at approximately $2,445,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the fourth quarter valued at $26,000. Gladius Capital Management LP raised its position in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 38,015 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer in the fourth quarter worth about $28,000. Noble Wealth Management PBC purchased a new position in Pfizer in the 4th quarter worth about $31,000. Finally, Teachers Insurance & Annuity Association of America purchased a new position in Pfizer in the 3rd quarter worth about $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE opened at $26.71 on Friday. The stock has a market cap of $151.35 billion, a PE ratio of 18.94, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The stock’s 50 day simple moving average is $26.30 and its 200-day simple moving average is $27.25.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the business posted $0.10 earnings per share. The business’s revenue was up 24.7% compared to the same quarter last year. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, January 24th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.44%. The ex-dividend date was Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is presently 121.99%.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Citigroup lowered their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Guggenheim restated a “buy” rating and issued a $33.00 target price on shares of Pfizer in a report on Monday, February 10th. Finally, Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.